A Clinical Study to Evaluate the Steady State Pharmacokinetics of Baraclude in Participants With Hepatitis B Virus Infection

Trial Profile

A Clinical Study to Evaluate the Steady State Pharmacokinetics of Baraclude in Participants With Hepatitis B Virus Infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Jul 2017 Planned end date changed from 1 Aug 2017 to 29 Sep 2017.
    • 10 Jul 2017 Planned primary completion date changed from 6 Jun 2017 to 3 Aug 2017.
    • 23 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top